Vai al contenuto principale

Dott.ssa Giulia Polverari

Attività di ricerca

  1. Ambrosini V, Campana D, Polverari G, Peterle C, Diodato S, Ricci C, Allegri V, Casadei R, Tomassetti P, Fanti S. Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas. J Nucl Med. 2015 Dec;56(12):1843-8.
  2. Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, Lodi F, Morganti AG, Ardizzoni A, Schiavina R, Fanti S. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1971-9.
  3. Polverari G, Ceci F, Graziani T, Cozzarini C, Castellucci P, Fanti S. A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT. Clin Genitourin Cancer. 2017 Jun;15(3):e525-e527.
  4. Angelini A, Ceci F, Castellucci P, Graziani T, Polverari G, Trovarelli G, Palmerini E, Ferrari S, Fanti S, Ruggieri P. The role of (18)F-FDG PET/CT in the detection of osteosarcoma recurrence. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1712-1720.
  5. Ceci F, Polverari G, Calais J, Castellucci P. The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2253-2255.
  6. Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by (68)Ga-PSMA-11 PET/CT. Clin Genitourin Cancer. 2019 Feb;17(1):e53-e55.
  7. Polverari G, Ceci F, Calderoni L, Cervati V, Farolfi A, Castellucci P, Fanti S. Male Breast Cancer Detected by (68)Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis. Clin Genitourin Cancer. 2019 Apr;17(2):154-156.
  8. Ceci F, Bianchi L, Borghesi M, Polverari G, Farolfi A, Schiavina R, Castellucci P, Fanti S. Prediction Nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. Eur J Nucl Med Mol Imaging. 2019 Sep 6.
  9. Bianchi L, Borghesi M, Schiavina R, Castellucci P, Ercolino A, Bianchi FM, Barbaresi U, Polverari G, Brunocilla E, Fanti S, Ceci F. Predictive accuracy and clinical benefit of a nomogram aimed to predict (68)Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database. Eur J Nucl Med Mol Imaging. 2020 Jan 31.
  10. Polverari G, Arena V, Ceci F, Pelosi E, Ianniello A, Poli E, Sandri A, Penna D. (18)F-Fluorodeoxyglucose Uptake in Patient With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Referred to Positron Emission Tomography/Computed Tomography for NSCLC Restaging. J Thorac Oncol. 2020 Mar 31.
  11. Polverari G, Ceci F, Bertaglia V, Reale ML, Rampado O, Gallio E, Passera R, Liberini V, Scapoli P, Arena V, Racca M, Veltri A, Novello S, Deandreis D. (18)F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival. Cancers (Basel). 2020 May 5;12(5).
  12. Ceci F, Castellucci P, Polverari G, Iagaru A. Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer. Curr Opin Urol. 2020 Sep;30(5):641-648.
  13. Polverari G, Ceci F, Passera R, Crane J, Du L, Li G, Fanti S, Bernthal N, Eilber FC, Allen-Auerbach M, Czernin J, Calais J, Federman N. [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. EJNMMI Res. 2020 Oct 15;10(1):122.
  14. Liberini V, De Santi B, Rampado O, Gallio E, Dionisi B, Ceci F, Polverari G, Thuillier P, Molinari F, Deandreis D. Impact of segmentation and discretization on radiomic features in 68Ga-DOTA-TOC PET/CT images of neuroendocrine tumor. EJNMMI Phys. 2021 Feb 27;8(1):21.
  15. Katsari K, Penna D, Arena V, Polverari G, Ianniello A, Italiano D, Milani R, Roncacci A, Illing RO, Pelosi E. Artificial intelligence for reduced dose 18F-FDG PET examinations: a real-world deployment through a standardized framework and business case assessment. EJNMMI Phys. 2021 Mar 9;8(1):25.
  16. Benz MR, Armstrong WR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, Quon A, Auerbach M, Girgis MD, Herrmann K, Czernin J, Calais J. 18F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma. J Nucl Med. 2021 Jul 16:jnumed.121.261952.
  17. Liberini V, Rubatto M, Mimmo R, Passera R, Ceci F, Fava P, Tonella L, Polverari G, Lesca A, Bellò M, Arena V, Ribero S, Quaglino P, Deandreis D. Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma. J Clin Med. 2021 Oct 27;10(21):4994.
  18. Canosa A, Martino A, Giuliani A, Moglia C, Vasta R, Grassano M, Palumbo F, Cabras S, Di Pede F, De Mattei F, Matteoni E, Polverari G, Manera U, Calvo A, Pagani M, Chiò A. Brain metabolic differences between pure bulbar and pure spinal ALS: a 2-[18F]FDG-PET study. J Neurol. 2023 Feb;270(2):953-959.

 

  1. Ambrosini V, Campana D, Peterle C, Nanni C, Polverari G, Cacciari G, Morigi JJ, Allegri V, Tomassetti P, Fanti S. Prognostic value of 68Ga-DOTA-NOC PET/CT SUVmax in patients with pancreatic NET. Oral presentation SNMMI 2014 Annual Meeting St. Louis MI, USA. Journal of Nuclear Medicine 55 (supplement 1), 560-560.
  2. Ambrosini V, Polverari G, Campana D, Cacciari G, Peterle C, Diodato S, Nanni C, Montini G, Tomassetti P, Fanti S. 68Ga-DOTA-NOC PET/CT SUVmax in patients with pancreatic NET: is it prognostic? Oral Presentation EANM 2014 Gothenburg, Sweden. Eur J Nucl Med Mol Imaging Supplements 2015. S232-S233.
  3. Polverari G, Ambrosini V, Gelsomino F, Diodato S, Ceci F, Sperandi F, Ardizzoni A, Fanti S. 18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results. Poster EANM 2016 Barcelona. Eur J Nucl Med Mol Imaging (2016) 43 (Suppl 1): S305-S305.
  4. Diodato S, Dika E, Chessa MA, Veronesi G, De Vivo S, Polverari G, Sanfilippo S, Sandler I, Nanni C, Fanti PA, Vaccari S, Patrizi A, Fanti S. Staging 18F-FDG PET/CT as a further determinant of prognosis in patients with cutaneous melanoma associated to Breslow thickness. Poster EANM 2016 Barcelona. Eur J Nucl Med Mol Imaging (2016) 43 (Suppl 1): S320-S320.
  5. Polverari G, Ceci F, Ambrosini V, Castellucci P, Guidalotti P, Campana D, Matti A, Lima GM, Fanti S. 18F-FDG PET/CT for restaging gastric cancer after surgical resection: is there a role in the assessment of local relapse? Oral presentation EANM 2016 Barcelona. Eur J Nucl Med Mol Imaging (2016) 43 (Suppl 1): S18-S18.
  6. Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, Morigi JJ, Ghedini P, Morganti AG, Schiavina R, Fanti S. 11C-choline PET/CT for restaging prostate cancer. Results in 4426 scans of a single-centre patient series. Poster EANM 2016 Barcelona. Eur J Nucl Med Mol Imaging (2016) 43 (Suppl 1):S328-S329.
  7. Lima GM, Matti A, De Crescenzo E, Polverari G, Perrone AM, De Iaco P, Nanni C, Fanti S. Prognostic value of 18F-FDG PET/CT in restaging of locally advanced cervical cancer after concomitant chemoradiation therapy. Oral Presentation EANM 2017 Vienna. Eur J Nucl Med Mol Imaging (2017) 44 (Suppl 2): S231-S232.
  8. Polverari G, Ceci F, Ambrosini V, Castellucci P, Guidalotti P, Matti A, Lima GL, Fanti S. The role of 18F-FDG-PET/CT to evaluate local recurrence in resected gastric cancer patients. Poster Walk AIMN 2017 Rimini, Italy.
  9. Polverari G, Ceci F, Calais J, Du L, Li G, Fanti S, Czernin J, Federman N. 18FDG PET/CT for evaluating early response to neoadjuvant-chemotherapy in pediatric patients with sarcoma. Results of a prospective single-center trial. Oral presentation EANM 2018 Düsseldorf, Germany. Eur J Nucl Med Mol Imaging (2018) 45 (Supplemental.): S186-S187.
  10. Ceci F, Polverari G, Gartmann J, Fendler W, Eiber M, Herrmann K, Czernin J, Calais J. Comparison of 68Ga-PSMA-11 PET/CT and 18F-Fluciclovine PET/CT in recurrent Prostate Cancer. Oral Presentation EANM 2018 Düsseldorf, Germany. Eur J Nucl Med Mol Imaging (2018) 45 (Supplemental.): S150-S150.
  11. Bianchi L, Ceci F, Borghesi M, Polverari G, Mineo Bianchi F, Barbaresi U, Chessa F, Castellucci P, Schiavina R, Fanti S, Brunocilla E. Which patient with biochemical recurrence after primary treatment for prostate cancer would result in a positive 68Ga-PSMA PET/CT? A clinical tool to guide physicians before suggesting 68Ga-PSMA PET/CT. Oral Presentation EAU 2019 Barcelona. European Urology (2019) 18 Supplements: e643-e644.
  12. Polverari G, Ceci F, Calais J, Du L, Li G, Fanti S, Czernin J, Federman N. 18FDG PET/CT performed early during neoadjuvant-chemotherapy to predict outcome in paediatric sarcoma patients. Results of a prospective single-center trial. Poster Walk AIMN 2019 Rimini, Italy. Lavoro selezionato tra i migliori del congresso ed esposto durante gli “highlights”.
  13. Bianchi L, Ceci F, Borghesi M, Polverari G, Mineo Bianchi F, Barbaresi U, Chessa F, Castellucci P, Schiavina R, Fanti S, Brunocilla E. PD15-10 WHICH PATIENT WITH BIOCHEMICAL RECURRENCE AFTER PRIMARY TREATMENT FOR PROSTATE CANCER WOULD RESULT IN A POSITIVE 68GA-PSMA PET/CT? A CLINICAL TOOL TO GUIDE PHYSICIANS BEFORE SUGGESTING 68GA-PSMA PET/CT. Oral Presentation AUA 2019 Chicago. The Journal of Urology Volume 201 Numero Supplement 4 Pagine e241-e242.
  14. Ceci F, Bianchi L, Borghesi M, Polverari G, Farolfi A, Schiavina R, Castellucci P, Fanti S. Prediction Nomograms for 68Ga-PSMA-11 PET/CT in different clinical stages of biochemical recurrence after radical therapy. Oral Presentation SNMMI 2019, Anaheim, California. Journal of Nuclear Medicine Volume 60 Numero supplement 1 Pagine 656-656
  15. Polverari G, Ceci F, Vada M, Castellucci P, Farolfi A, Calderoni L, Lodi F, Fanti S. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical persistence (BCP) after radical prostatectomy. Accuracy in localizing residual disease and impact on subsequent management. e-poster EANM 2019 Barcelona, Spain.
  16. Ceci F, Bianchi L, Borghesi M, Polverari G, Farolfi A, Schiavina R, Castellucci P, Fanti S. Prediction Nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. Oral Presentation EANM 2019 Barcelona, Spain.
  17. Polverari G, Ceci F, Bertaglia V, Reale ML, Rampado O, Gallio E, Passera R, Liberini V, Scapoli P, Arena V, Racca M, Veltri A, Novello S, Deandreis D. 18F-FDG PET Parameters and Radiomics Features Analysis in Advanced NSCLC treated with Immunotherapy as Predictors of Therapy Response and Survival. Oral e-poster EANM 2020 Vienna, Austria.
  18. Rampado O, Gallio E, Liberini V, Ropolo R, Ceci F, Polverari G, Dionisi B, Molinari F, Deandreis D. Impact of intensity discretization on radiomics analyisis in 68Ga-DOTATOC PET/CT for Neuroendocrine Tumor. Poster ECMP 2020.
  19. Armstrong WR, Benz MR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, Quon A, Allen Auerbach M, Girgis MD, Herrmann K, Czernin J, Calais J. F-FDG PET/CT Combined Metabolic-Radiographic biomarker for Early Prediction of first line Chemotherapy Outcomes in PDAC: a single center prospective study. Oral Presentation SNMMI 2021 Washington, D.C.
  20. Liberini V, Mimmo R, Passera R, Califaretti E, Ceci F, Fava P, Rubatto M, Ribero S, Polverari G, Arena V, Bello M, Quaglino P, Deandreis D. “Predictive value of baseline [18F]FDG PET/CT for response to systemic therapy in patients with advanced melanoma. Top Rated Oral Presentation. EANM 2021.
  21. Polverari G, Canosa A, Martino A, Giuliani A, Moglia C, Vasta R, Palumbo F, De Mattei F, Matteoni E, Daviddi M, Fuda G, De Marco G, Pagani M, Calvo A, Chiò A, Manera U. Sex-related differences in Amyotrophic Lateral Sclerosis: a brain 2-[18F]FDG-PET study. Oral Presentation. ECCN 2023.

  1. Polverari G, Ambrosini V, Fanti S. La diagnostica PET/TC nei tumori neuroendocrini. Springer 2016. L'Endocrinologo 17 (5), 233-236.
  2. Polverari G, Ambrosini V, Fanti S. Capitolo 10 “Ruolo della 18F-FDG PET/TC” del libro “Carcinoma della giunzione gastro-esofagea e dello stomaco” edito da Il Pensiero Scientifico Editore.
  3. Polverari G, Penna D, Cassalia L, Deandreis D, Pelosi E. Chapter 29 “Diagnostic Applications of Nuclear Medicine: Colorectal Cancer” Third Edition of the Nuclear Oncology: From Pathophysiology to Clinical Applications, edited by Duccio Volterrani, Paola A. Erba, H. William Strauss, Giuliano Mariani and Steven M. Larson. Springer.
  4. Polverari G, Lambertini A, Fanti S, Ceci F. Chapter 18 “18F-Choline, 68Ga-PSMA-11 and 18F-FDG PET/CT in Treatment Response Evaluation: Prostate Cancer” of the Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology edited by Stefano Fanti, Gopinath Gnanasegaran and Ignasi Carrio. Springer.
  5. Rovera G, Polverari G, Ceci F. Chapter 3 “Prostate Specific Membrane Antigen (PSMA) as probe for new generation PET imaging”. Nuclear Medicine in Prostate Cancer Management edited by Laura Evangelista and Francesco Ceci. Edizioni Minerva Medica

  1. Relatore al congresso: 29th ANNUAL CONGRESS of the EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE – EANM’16, Barcelona, Spain, dal 15-10-2016 al 19-10-2016. Abstract selezionato come presentazione orale: 18F-FDG PET/CT for restaging gastric cancer after surgical resection: is there a role in the assessment of local relapse?
  2. Relatore al congresso: XIII congresso nazionale AIMN 2017, Rimini, Italy dal 2-03-17 al 5-03-17. Abstract selezionato come poster walk con presentazione orale: The role of 18F-FDG-PET/CT to evaluate local recurrence in resected gastric cancer patients.
  3. Relatore al congresso: 31th ANNUAL CONGRESS of the EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE – EANM’18, Düsseldorf, Germany, dal 13-10-18 al 17-10-18. Abstract selezionato come presentazione orale: 18FDG PET/CT for evaluating early response to neoadjuvant-chemotherapy in pediatric patients with sarcoma. Results of a prospective single-center trial.
  4. Relatore al congresso: XIV congresso nazionale AIMN 2019, Rimini, Italy dal 11-04-19 al 14-04-19. Abstract selezionato come poster walk con presentazione orale: 18FDG PET/CT performed early during neoadjuvant-chemotherapy to predict outcome in paediatric sarcoma patients. Results of a prospective single-center trial.
  5. Relatore al congresso: 33th ANNUAL CONGRESS of the EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE –  EANM' 20 VIRTUAL, October 22-30, Vienna, Austria. Abstract selezionato come poster walk con presentazione orale: 18F-FDG PET Parameters and Radiomics Features Analysis in Advanced NSCLC treated with Immunotherapy as Predictors of Therapy Response and Survival.
  6. Relatore al Congresso: Meeting with Neurologist and Geriatrician, Moncalieri Hospital, October 2021. Title of the invited lecture: “Applicazione della PET nelle malattie neurodegenerative: incontro con i neurologi e geriatri”.
  7. Relatore al Congresso: Neurological Meeting, Ivrea Hospital, April 2022. Title of the invited lecture “Applicazione della PET cerebrale nelle malattie neurodegenerative: Il mercoledì con l’esperto”.
  8. Relatore al Congresso:European Association of Nuclear Medicine, Annual Conference October 2022, Barcelona, Spain. Title of the invited lecture: “Tricky Cases in Gastro-Esophageal Cancer”.
  9. Relatore al Congresso:Meeting with Neurologist and Geriatrician, Moncalieri Hospital, January 2023. Title of the invited lecture “18F-DOPA PET and 123I-Ioflupane (DaTSCAN) in Parkinsonism Syndrome”.
  10. Relatore al Congresso:11th European Conference on Clinical Neuroimaging ECCN, Genoa, March 2023. Title of the oral communication “Sex-related differences in Amyotrophic Lateral Sclerosis: a brain 2-[18F]FDG-PET study”.
  11. Relatore al Congresso:European Association of Nuclear Medicine, Annual Conference September 2023, Vienna, Austria. Title of the invited lecture “Amyloid or Tau PET - What First in Alzheimer Dementia Patients

29/07/2021: Fitting regression models: interpretation of regression coefficients, uncertainty measures and hypothesis testing. Prof. Maule

31/08/2021: Update on physiology of hypertension. Prof. Veglio

02/09/2021: Diabetic nephropathy. Prof. Gruden

06/09/2021: Precision medicine in oncology: Putting drivers and targets in context. Prof. Trusolino

13/09/2021: Targets for functional imaging in medicine. Prof. Deandreis

14/09/2021: Impact of the metabolic syndrome on the digestive tract. Prof. Bugianesi

23/09/2021: Regression models: from the linear model to the generalised linear models. Interpretation of interactions between predictors. Prof. Maule

1/06/23: Alteration of intestinal microbioma as organ insufficiency: practical implications. Prof. De Rosa

6/06/23: Biology and Diagnosis of SARS CoV2. Prof. Costa

08/06/23: Cardiac electric physiopathological properties. Prof. De Ferrari

08/06/23: Therapeutic strategies for liver transplant. Prof Romagnoli

Ultimo aggiornamento: 05/10/2023 11:49
Non cliccare qui!